- RecruitingPHASE2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new drug, TAK-279, for people aged 18-75 with Crohn's disease that isn't well-controlled. We want to see if it reduces gut inflammation and is safe, compared to a dummy drug. It lasts about one year.
For: Crohn's DiseaseUnited States · Australia · Belgium - Active not recruitingPHASE2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called TAK-279 for adults with moderate to severe ulcerative colitis. It aims to see if it reduces bowel inflammation and symptoms compared to a dummy medicine, and to check for any side effects.
For: Ulcerative ColitisUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine called TAK-279 for moderate to severe plaque psoriasis. It aims to see how safe the medicine is and how well people tolerate it, building on earlier studies. It involves participants taking the medicine for up to four years.
For: Plaque PsoriasisUnited States · Argentina · Australia